Analysis of blood plasma proteins in patients with Alzheimer's disease by two-dimensional electrophoresis, sequence homology and immunodetection

Ueno, Ikuko; Sakai, Tomoko; Yamaoka, Makoto; Yoshida, Ryoichi; Tsugita, Akira

doi:10.1002/(sici)1522-2683(20000501)21:9<1832::aid-elps1832>3.0.co;2-7

Cited by 36 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 2D-PAGE study detected 350 silver-stained proteins in the plasma of six control cases, five AD cases, and three non-AD dementias, of which 73 spots were identified by sequencing or immunostaining, including the AD-related proteins apoE, tau, and presenilin-2. 113 The complexity of serum and plasma, imprecision of peak matching in mass spectroscopy and spot matching in 2D-PAGE, and difficulties in assay standardization make these approaches challenging, but advances in technology platforms and bioinformatics will allow broader applicability to diseases such as AD.…”

Section: Biomarker Profilingmentioning

confidence: 95%

Biomarkers of Alzheimer disease in plasma

Irizarry

2004

Neurotherapeutics

View full text Add to dashboard Cite

Summary: Plasma and serum biochemical markers proposed for Alzheimer disease (AD) are based on pathophysiologic processes such as amyloid plaque formation [amyloid ␤-protein (A␤), A␤ autoantibodies, platelet amyloid precursor protein (APP) isoforms], inflammation (cytokines), oxidative stress (vitamin E, isoprostanes), lipid metabolism (apolipoprotein E, 24S-hydroxycholesterol), and vascular disease [homocysteine, lipoprotein (a)]. Most proteins or metabolites evaluated in plasma or serum thus far are, at best, biological correlates of AD: levels are statistically different in AD versus controls in some cohorts, but they lack sensitivity or specificity for diagnosis or for tracking response to therapy. Approaches combining panels of existing biomarkers or surveying the range of proteins in plasma (proteomics) show promise for discovering biomarker profiles that are characteristic of AD, yet distinct from nondemented patients or patients with other forms of dementia.

show abstract

Section: Biomarker Profilingmentioning

confidence: 95%

Biomarkers of Alzheimer disease in plasma

Irizarry

2004

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…proteins that differed between AD and control cases (Ueno et al, 2000). In another proteomic case-control study the combination of several molecules gave a sensitivity of 56% and specificity of 80% (Hye et al, 2006).…”

Section: Biomarkers In Plasmamentioning

confidence: 99%

Biomarkers for Alzheimer’s disease and other forms of dementia: Clinical needs, limitations and future aspects

Cedazo-Minguez

Winblad

2010

Experimental Gerontology

137

133

View full text Add to dashboard Cite

To cite this version:Angel Cedazo-Minguez, Bengt Winblad. Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. Experimental Gerontology, Elsevier, 2009, 45 (1), pp. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT

show abstract

“…30 The study included a limited number of samples, and further studies are needed to determine whether the identified proteins can be used as potential biomarkers for AD. Another study divided the 100 samples into two equal sets: a test set and a replication set.…”

Section: Proteinsmentioning

confidence: 99%

“…30,46 The use of a set of 18 polypeptides or a set of fewer than 96 gene-expression assays show both high specificity and sensitivity and have the potential to simultaneously measure changes in several biological processes associated with AD.…”

Section: Biomarkers For the Futurementioning

confidence: 99%

Blood Biomarkers for Alzheimer’s Disease

Winblad¹,

Lönneborg²

2008

European Neurological Review

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a multifactorial and heterogeneous disease in both its clinical and histopathological appearance. In more than 99% of cases the cause of the disease is not understood. Independent of its cause, AD is clinically characterised by a developing dementia and histopathologically characterised by neuronal degeneration.Although the presence of neurofibrillary tangles (NFTs) and neurotic The development of biomarkers for AD is challenging as it is complicated by several factors. In addition to the variability in clinical features and multiple molecular aetiologies, the development of AD biomarkers is burdened with a diagnostic imprecision as confirmation of the disease preferentially has to await a post mortem histopathological examination.The long asymptomatic prodromal stages, rates of progression and complex disease genetics complicate the situation further. In this article we will review the current developments in the field of biomarkers for the detection of AD in blood. Single-component BiomarkersThe physiology of the blood-brain barrier limits potential biomarkers that are closely associated to brain pathophysiology to small molecules, lipophilic molecules and molecules with specific transporters. 12 Brainderived proteins and metabolites that pass into the plasma will also become markedly diluted in a biochemically complex medium. 12 Moreover, it is not known whether there are any direct pathophysiological processes associated with AD in blood cells. The traditional approach of using one or a few closely related molecules as a biomarker, a single-component biomarker, in plasma, serum or blood has been utilised since the late 1990s. [13][14][15] However, their usefulness has been limited, mainly due to discrepant results between studies. Amyloid β-proteinAβ can be detected in plasma and is thus a compelling candidate biomarker for AD. The plasma total Aβ or Aβ42 was increased in familial AD with presenilin or APP mutations 16,17 and in Down's syndrome with APP triplication, 18 which raises the possibility that sporadic AD may also be associated with detectable and diagnostic changes in Aβ plasma levels. Animal models suggest that Aβ can pass between cerebrospinal fluid (CSF) and plasma compartments, 19,20 but this has yet to be confirmed in humans. APP is also produced by platelets and is, therefore, an alternative source for the APP and Aβ pools found in plasma.

show abstract

Analysis of blood plasma proteins in patients with Alzheimer's disease by two-dimensional electrophoresis, sequence homology and immunodetection

Cited by 36 publications

References 30 publications

Biomarkers of Alzheimer disease in plasma

Biomarkers of Alzheimer disease in plasma

Biomarkers for Alzheimer’s disease and other forms of dementia: Clinical needs, limitations and future aspects

Blood Biomarkers for Alzheimer’s Disease

Contact Info

Product

Resources

About